The estimated Net Worth of Andrew Hull is at least 11.1 千$ dollars as of 21 February 2024. Andrew Hull owns over 37,500 units of InMed Pharmaceuticals stock worth over 11,095$ and over the last 3 years Andrew sold INM stock worth over 0$.
Sign up
Andrew Hull INM stock SEC Form 4 insiders trading
Andrew has made over 1 trades of the InMed Pharmaceuticals stock since 2024, according to the Form 4 filled with the SEC. Most recently Andrew bought 37,500 units of INM stock worth 14,625$ on 21 February 2024.
The largest trade Andrew's ever made was buying 37,500 units of InMed Pharmaceuticals stock on 21 February 2024 worth over 14,625$. On average, Andrew trades about 6,250 units every 0 days since 2021. As of 21 February 2024 Andrew still owns at least 38,258 units of InMed Pharmaceuticals stock.
You can see the complete history of Andrew Hull stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Andrew Hull's mailing address?
Andrew's mailing address filed with the SEC is C/O INMED PHARMACEUTICALS INC., 310-815 WEST HASTINGS ST., VANCOUVER, A1, V6C1B4.
Insiders trading at InMed Pharmaceuticals
Over the last 4 years, insiders at InMed Pharmaceuticals have traded over 43$ worth of InMed Pharmaceuticals stock and bought 153,613 units worth 127,277$ . The most active insiders traders include William J Garner、Eric A Adams、Andrew Hull. On average, InMed Pharmaceuticals executives and independent directors trade stock every 86 days with the average trade being worth of 3,718$. The most recent stock trade was executed by Alexandra Diane Janet Mancini on 31 July 2024, trading 240 units of INM stock currently worth 43$.
What does InMed Pharmaceuticals do?
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
What does InMed Pharmaceuticals's logo look like?
Complete history of Andrew Hull stock trades at InMed Pharmaceuticals
InMed Pharmaceuticals executives and stock owners
InMed Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Eric A. Adams,
Pres, CEO & Director -
Bruce S. Colwill C.A., CPA, CA,
CFO & Corp. Sec. -
Alexandra Diane-Janet Mancini,
Sr. VP of Clinical & Regulatory Affairs -
Brenda Edwards C.M.A., CPA,
Interim Chief Financial Officer -
Dr. Ado Muhammad,
Sr. Consultant of Medical Affairs -
Dr. Shane A. Johnson Ph.D.,
Sr. VP & GM of BayMedica -
Michael Woudenberg P.Eng.,
Sr. VP of Chemistry, Manufacturing & Controls -
Dr. Eric Chih-Hsien Hsu,
Sr. VP of Preclinical R&D -
Jerry P. Griffin,
VP of Sales & Marketing -
Colin Clancy,
Sr. Director of Investor Relations -
Dr. Sazzad Hossain M.Sc., Ph.D.,
Co-Founder -
Andrew Hull,
Director -
William J Garner,
Director -
Sarah Li,
VP Accounting & Controller -
Janet P Grove,
Director -
Eric C Hsu,
Sr. VP, Pre-Clinical Res/Dev -
Catherine Sazdanoff,
Director -
Adam D. Cutler,
Director -
Michael Woudenberg,
Chief Operating Officer -
Eric A Adams,
President & CEO -
Bruce Colwill,
CFO -
Bryan T Baldasare,
Director -
Nicole Lemerond,
Director -
Jonathan Tegge,
Interim CFO -
Shane Aaron Johnson,
Sr VP & General Manager